National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 46 of 66
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
NCT00096265
XK469R in Treating Patients With Refractory Hematologic Cancer
NCT00095797
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
NCT00107432
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
NCT00095940
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
NCT00091182
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
NCT00098813
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
NCT00098670
CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
NCT00098501
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
NCT00118170
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
NCT00098891
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00101296
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
NCT00093626
Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
NCT00098631
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
NCT00098605
Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
NCT00098579
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
NCT00095693
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
NCT00095888
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
NCT00098527
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
NCT00101231
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT00098618
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00096148
Exercise in Women at Risk for Breast Cancer
NCT00092950
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
NCT00096278
Vaccine Treatment of Kidney Cancer
NCT00089778
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
NCT00340522
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
NCT00341939
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
NCT00090545
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00085280
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
NCT00098969
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
NCT00087412
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
NCT00087139
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
NCT00093756
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00101114
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
NCT00096122
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT00095966
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
NCT00093418
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
NCT00093821
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
NCT00091130
Sorafenib in Treating Patients With Metastatic Breast Cancer
NCT00096434
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
NCT00091195
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
NCT00089089
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
NCT00091611
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
NCT00093470
Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery
NCT00091039
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338
Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00089154
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096200
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
NCT00088907
Genetic Analysis of Psoriasis and Psoriatic Arthritis
NCT00341809
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.